Bipolar Depression
Conditions
Keywords
TMS, Treatment, Bipolar, Efficacy
Brief summary
This is a study to assess the effectiveness of repetitive transcranial magnetic stimulation (rTMS) as a treatment for depressed adults with bipolar disorder. In rTMS high-intensity, fluctuating magnetic fields non-invasively stimulate the cortex of the brain depolarising neurons. No anaesthetic is required and the treatment in subconvulsive. Recent studies suggest that rTMS can be an effective treatment for depressive illness in adults (Loo and Mitchell et al, 2005) and appears to be quite safe. Most of the published studies to date have focused on unipolar depression. There is limited data of TMS use in bipolar depression. Eg. Pilot study by Nahas Z, Kozel FA, Li X, Anderson B, George MS.in 2003, which was negative. The investigators wish to assess this in a sham-controlled study of adults. The investigators hypothesise that both left and right sided rTMS will have an antidepressant effect superior to sham in this population.
Detailed description
Inpatients and outpatients with major depressive episodes as part of either bipolar I or II illness will be eligible. In the event that patients (in any arm) have no significant response after a defined period, they will shift to an open phase where they will receive left prefrontal 10Hz stimulation. Thus all participants will have the opportunity to receive active treatment.
Interventions
DEVICETranscranial Magnetic Stimulation
Sponsors
The University of New South Wales
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* DSM-IV Major Depressive Episode of no more than 3 years. * Diagnosis of bipolar I or II disorder * Montgomery-Asberg Depression Rating Scale score of 20 or more. * Aged over 18 * May or may not be taking antidepressant medication.
Exclusion criteria
* Patient not able to give informed consent. * Failure to respond to ECT in current episode of depression. * Significant other Axis I psychiatric disorders e.g. schizophrenia. * In imminent physical or psychological danger, or needs rapid clinical response due to inanition, psychosis or high suicide risk. * Comorbid substance abuse or dependence * History of neurological illness e.g. epilepsy; neurosurgical procedure * Metal in the cranium, a pacemaker, cochlear implant, medication pump or other electronic device. * Women of child-bearing age in whom pregnancy cannot be ruled out. * Patients with a history of mood 'switching' in response to other treatments.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All measures at baseline and at the end of each week of treatment in the blind phase and after every 2 weeks of treatment in the open phase. | weekly |
| Montgomery-Asberg Depression Rating Scale (MADRS) | Weekly |
| Clinical Global Impressions Scale (CGI) | Weekly |
Secondary
| Measure | Time frame |
|---|---|
| Patient Global Improvement scale | Weekly |
| Young Mania Rating Scale | weekly |
Countries
Australia
Outcome results
None listed